Where Scientists Meet Antibody Success
ProSci specializes in catalog antibody products and custom antibody development services. For over 25 years, we have offered a combination of developing catalog antibodies, providing antibody services, and conducting antibody-related R&D. This makes ProSci unique in the antibody market in the US and worldwide.
Learn more about our catalog of antibody products.
Catalog Antibody Products
We began by developing and marketing antibodies against novel targets, including apoptosis molecules and HIV coreceptors. ProSci expanded its antibody product lines to signal transduction, cancer, neurology, and immuno-oncology. ProSci has established efficient capabilities to develop diverse antibody lines, including affinity purified polyclonal antibodies, hybridoma lines, and recombinant antibodies. We have established an extensive antibody validation program to provide specific and reproducible products to the antibody market.
Custom Antibody Services (CAS)
ProSci provides custom antibody development services, including polyclonal, monoclonal, rabbit recombinant, and single domain, against a large diversity of antigens. From proteins and peptides, to small molecules and carbohydrates, idiotypes, and whole cells. ProSci continues to deliver antibodies for many difficult projects such as single amino acid mutation specific, peptide terminal specific, self-carbohydrates from N-glycans, GPCRs, etc. The combination of a highly experienced scientific team and an incredible customer care team facilitates delivers to a wide array of customers including academia, government, biotech, diagnostic, and pharmaceutical companies.
Antibody Focused R&D
ProSci led a multi-year R&D project to develop broadly neutralizing antibodies by targeting the viral glycan shield for an HIV vaccine. This study resulted in one patent, six peer reviewed publications, and multiple SBIR awards from NIH. This 15+ year study built a profound foundation for successfully developing various challenging custom antibodies. ProSci has established its own proprietary techniques to develop single domain antibodies (sdAbs) with picomolar affinity for diagnostic and therapeutic applications. A pipeline of sdAbs against immune checkpoint targets is currently in various stages of development.
ProSci’s antibody service capability, gained from its extensive antibody focused R&D, catalog antibody development and over 25,000 custom antibodies in its 25+ year history, assures confidence and ease to achieve customized antibody success.